National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Durvalumab (Imfinzi®) is indicated for for the treatment of locally advanced, unresectable Non-small cell lung cancer (NSCLC)  in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)1.


NCPE Assessment Process Ongoing
Rapid review commissioned 29/03/2019
Rapid review completed 29/04/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/05/2019
Pre-submission consultation with Applicant 10/06/2019
Submission received from Applicant 30/08/2019
Current Status Submission received from Applicant